The Enfamil and Similac NEC class action litigation represents a major legal battle over whether two of America’s largest infant formula manufacturers—Abbott Laboratories (maker of Similac) and Mead Johnson (maker of Enfamil)—knowingly withheld warnings about a serious medical risk to premature and at-risk newborns. Necrotizing enterocolitis (NEC) is a devastating intestinal condition that can cause tissue death, require emergency surgery, result in permanent disability, or prove fatal. Lawsuits filed across the United States allege that these manufacturers understood that cow milk-based formulas posed a higher risk of NEC compared to alternatives like human milk fortifiers or specialized hydrolyzed formulas, but failed to adequately warn consumers or healthcare providers of this danger. Parents have filed hundreds of claims seeking compensation for their children’s medical injuries, surgeries, lifelong health complications, and in some tragic cases, death. The legal case has reached a critical stage.
As of early 2026, between 769 and 779 active lawsuits are consolidated in the U.S. District Court for the Northern District of Illinois in what’s called a multidistrict litigation (MDL), overseen by Judge Rebecca R. Pallmeyer. This consolidation, which began in April 2022, allows the courts to manage similar claims efficiently while bellwether trials (test cases that predict how juries will likely rule on larger groups of claims) move forward. Recent verdicts have delivered substantial damages to plaintiffs: a $60 million verdict against Mead Johnson in Illinois state court in March 2024, a dramatic $495 million total damages award in Missouri state court earlier in 2026, and a single case verdict awarding $95 million in compensatory damages plus $400 million in punitive damages against Abbott. These results reflect growing recognition from juries that the manufacturers bear responsibility for harm caused by their products.
Table of Contents
- What Is Necrotizing Enterocolitis and Why Does Formula Type Matter?
- How Did the Class Action Litigation Develop and What Are the Current Legal Phases?
- What Do Plaintiffs Allege the Manufacturers Knew and Did Not Disclose?
- What Verdicts and Compensation Have Been Awarded So Far?
- What Are the Key Limitations and Risks in Pursuing an NEC Formula Claim?
- How Do Formula Cases Compare to Other Product Liability Litigation?
- What Is the Current Status and What Might Families Expect Going Forward?
What Is Necrotizing Enterocolitis and Why Does Formula Type Matter?
necrotizing enterocolitis is a medical emergency affecting the intestines of premature or critically ill newborns, typically those born before 32 weeks of gestation or weighing less than 1,500 grams. The condition causes inflammation and tissue death in the intestines, potentially leading to intestinal perforation, sepsis, and life-threatening complications. Medical research has consistently shown that premature infants fed cow milk-based formulas face a higher risk of developing NEC compared to infants receiving human breast milk or specialized formulas designed to reduce NEC risk. A 2020 meta-analysis and numerous peer-reviewed studies have documented this connection, yet the infant formula manufacturers continued marketing cow milk-based products like Similac and Enfamil to hospitals and families as safe feeding options without adequately highlighting the NEC risk differential. The difference in outcomes is significant. Infants who develop NEC may require multiple emergency surgeries to remove dead intestinal tissue, develop short bowel syndrome (requiring lifelong nutritional support through feeding tubes or intravenous nutrition), experience chronic digestive problems, suffer developmental delays from prolonged hospitalization and illness, or die from the condition despite aggressive medical intervention.
For example, a family in a recent bellwether trial reported that their premature daughter, fed Similac in the hospital without knowledge of formula-related NEC risks, developed the condition at two weeks of age. She required emergency surgery, spent months in the NICU fighting infection and complications, and now requires ongoing medical care and therapy at age five. The family’s damages included not only past medical bills but also the cost of her future care needs. Had they known about the increased risk with cow milk formulas, they likely would have requested or advocated for human milk fortifier or hydrolyzed formula options. Hospitals and neonatal intensive care units face decisions about which formulas to stock and recommend. Many relied on the marketing and assurances from abbott and Mead Johnson that their formulas were safe without understanding the published medical evidence about NEC risk stratification by formula type. This information asymmetry—where manufacturers had access to research showing NEC risk differences but did not transparently communicate this to healthcare providers and parents—is central to the lawsuits’ allegations of negligence and fraud.
How Did the Class Action Litigation Develop and What Are the Current Legal Phases?
The multidistrict litigation consolidated in the Northern District of Illinois represents hundreds of individual lawsuits originally filed in various state and federal courts across the country. The consolidation process began in April 2022 when federal judges determined that having many similar NEC formula claims heard in different courts would create conflicting rulings and inefficiency. Judge Rebecca R. Pallmeyer was assigned to oversee the MDL, and she established procedures to handle discovery (the exchange of evidence between parties), expert testimony about the medical and scientific issues, and eventually trials. Between 769 and 779 lawsuits remain active in the MDL as of early 2026, though the actual number of affected families is likely much higher—some claims may be pending resolution in state court systems, while others are being evaluated by attorneys before formal filing. The litigation has moved into the bellwether trial phase, where a small number of representative cases are tried first to give both sides an indication of how juries might decide similar claims. A significant plaintiff victory occurred in December 2025, which led to the court scheduling additional bellwether trials throughout 2026.
These test trials are crucial because their outcomes often influence settlement negotiations and the willingness of both sides to reach broader agreements. In a bellwether trial, one or more families present their case to a jury, which hears evidence about whether the manufacturers knew of NEC risks, whether they failed to warn, and what damages should be awarded. The verdicts from these trials—including the $60 million Illinois judgment against Mead johnson in March 2024 and the extraordinary $495 million damages award in Missouri earlier in 2026—signal that juries are finding liability and awarding substantial compensation. However, there is an important limitation to understand: even as individual cases win large verdicts, the overall litigation remains in active trial and settlement phases. No company-wide settlement agreement covering all affected families has been finalized as of April 2026. This means that families seeking compensation still need to file individual claims, provide medical evidence of their child’s NEC diagnosis and formula use, and potentially participate in the legal process. The timeline for resolution of all pending cases could extend several more years depending on the court’s scheduling and the outcome of additional bellwether trials.
What Do Plaintiffs Allege the Manufacturers Knew and Did Not Disclose?
Central to these lawsuits is the allegation that Abbott Laboratories and Mead Johnson possessed knowledge—through their own research, published medical literature, and communications from healthcare providers—that cow milk-based infant formulas carried a higher risk of necrotizing enterocolitis in premature and at-risk infants compared to alternatives like human milk fortifiers or specialized hydrolyzed formulas. The plaintiffs’ legal teams argue that this knowledge was not adequately communicated to doctors, hospitals, and parents through warnings on product labels, educational materials, or direct communication to healthcare providers. Instead, the manufacturers continued to market and sell their cow milk-based formulas heavily to NICUs and families, including through sales representatives, hospital contracts, and consumer marketing. Plaintiffs’ attorneys have pointed to internal company communications and scientific studies in discovery that suggest the manufacturers were aware of the NEC risk differential. For example, they cite research presented at pediatric medical conferences, correspondence with regulatory agencies, and internal risk assessments that reportedly acknowledged the advantages of breast milk or hydrolyzed formulas in reducing NEC risk.
Yet the marketing and product positioning often emphasized safety and nutrition without clearly stating that premature infants receiving cow milk-based formulas had a measurably higher NEC risk than those receiving alternatives. In one bellwether case that reached trial, the jury heard evidence that a hospital’s neonatal team would have made a different feeding recommendation if they had received complete information from the formula manufacturer about NEC risk stratification by formula type. The legal concept at issue is failure to warn—a product liability theory that holds a manufacturer responsible for injury caused by a product when the manufacturer failed to provide adequate warnings about known or knowable hazards. The plaintiffs argue this is not about the formula being inherently “defective” in a manufacturing sense, but rather about the manufacturers’ obligation to share material safety information that would affect a healthcare provider’s or parent’s decision-making. This distinction matters for the legal theories pursued in the cases.
What Verdicts and Compensation Have Been Awarded So Far?
Recent trial outcomes have resulted in significant damage awards that demonstrate how juries are weighing the manufacturers’ responsibility. The most impactful verdict to date came in Missouri state court in early 2026, where a jury awarded $495 million in total damages against Abbott Laboratories. This verdict combined compensatory damages (meant to reimburse the family for medical expenses, pain and suffering, and future care needs) with punitive damages (meant to punish the manufacturer for egregious conduct and deter similar behavior). In another case that proceeded to verdict, a jury awarded $95 million in compensatory damages plus $400 million in punitive damages, with Abbott found liable. These punitive damage awards are particularly significant because they indicate that juries believe the manufacturers’ conduct was not merely negligent but willful or reckless. Comparing these awards to other major product liability settlements illustrates their scale. The $60 million verdict against Mead Johnson in Illinois state court in March 2024 was substantial but preceded the even larger Missouri award. When settlements do finalize for larger groups of claimants, individual awards typically range from thousands to hundreds of thousands of dollars depending on the severity of the child’s injury, the medical expenses incurred, the prognosis, and the strength of evidence in that particular case.
However, compensation structures vary significantly. Some families receive lump-sum awards, while others in settlement programs might receive funds distributed over time or allocated according to a claims matrix that adjusts for injury severity. A key tradeoff families face is whether to pursue an individual trial (which could result in a large award but involves litigation risk and uncertainty) or wait for a potential settlement program (which might offer a faster, more certain resolution but potentially lower compensation). These verdicts come after families navigated years of medical crisis, financial burden, and emotional trauma. A family whose premature infant developed NEC might have faced six months or longer in the NICU, followed by multiple surgeries, potential permanent feeding difficulties, developmental delays, and ongoing medical appointments and therapies for years after discharge. Medical costs for severe NEC cases can exceed $500,000 to $1 million or more. Beyond the financial aspects, families deal with the guilt of worrying whether formula choices contributed to their infant’s condition, the stress of their child’s medical complications, and in tragic cases, the loss of a child. The litigation offers a mechanism for holding manufacturers accountable and providing financial resources to support ongoing care needs.
What Are the Key Limitations and Risks in Pursuing an NEC Formula Claim?
Families considering whether to file an NEC formula claim face several important limitations and challenges. First, proving causation—demonstrating that the specific formula fed to their child actually caused the NEC—is medically and legally complex. NEC is a multifactorial condition, meaning it typically results from a combination of factors including prematurity, infection, feeding practices, and gut immaturity. While research shows that cow milk-based formulas increase NEC risk compared to alternatives, an individual child’s NEC cannot definitively be attributed solely to formula choice. Families must work with medical experts who can review the child’s medical records, identify that a cow milk-based formula was fed, and establish that the manufacturers’ failure to warn about NEC risk was a substantial factor in the family’s inability to make a better-informed decision. This requires detailed medical documentation from the hospital and NICU where the child was treated. A second major limitation is the statute of limitations—the legal deadline by which a claim must be filed. These deadlines vary by state and the type of claim (personal injury versus wrongful death), typically ranging from two to four years from the date of injury or from when the plaintiff discovered or reasonably should have discovered the harm.
For NEC diagnosed in a newborn, the clock may start ticking from the date of NEC diagnosis. Families who did not immediately suspect that formula choice played a role in their child’s condition, or who were focused on the medical crisis at the time, might not have filed within the deadline if they didn’t pursue the claim quickly. This is why it’s critical for families to consult with attorneys as soon as they become aware that their child’s NEC may be formula-related, rather than waiting years later. A third warning concerns the information families must gather. Medical records from the NICU, documentation of which specific formula products were used and for how long, hospital feeding protocols and any communications about formula selection, and expert medical opinions linking the formula use to NEC risk are all necessary. Families should request complete copies of their child’s medical records from the hospital, including feeding documentation, immediately if they haven’t already done so. In some cases, hospitals or healthcare providers may be reluctant to provide full documentation or to comment on how formula was selected, particularly if they fear their own liability exposure. However, families have a legal right to obtain their medical records. Additionally, the longer the delay in gathering documentation, the greater the risk that records may be lost, destroyed as part of routine record retention policies, or become less accessible.
How Do Formula Cases Compare to Other Product Liability Litigation?
The Enfamil and Similac NEC litigation shares similarities with other major product liability cases but has some distinct characteristics. Like talc litigation (claims that talc powder causes ovarian cancer or mesothelioma), the NEC formula cases turn on whether a manufacturer failed to warn about health risks associated with a product used for a vulnerable population. Like drug liability cases, NEC claims involve complex medical causation and the interpretation of scientific research. However, infant formula cases carry a unique emotional and medical weight because they involve the feeding of newborns and premature infants—a population that cannot consent to or refuse the product and that is entirely dependent on parents and healthcare providers to make decisions on their behalf.
The role of hospital NICUs in these cases also distinguishes them from some consumer product lawsuits. Many NEC cases involve formula selected and administered by healthcare providers in hospital settings, not by parents purchasing formula over-the-counter at home. This means that discovery and evidence often includes hospital protocols, purchasing decisions, physician training on formula risks, and relationships between formula manufacturers and hospitals. Some hospitals received financial relationships, discounts, or marketing support from formula manufacturers, which raises additional questions about whether those relationships influenced formula selection independent of clinical reasoning. Understanding this hospital-centered context is important for families evaluating their own cases, as the strength of their claim may depend partly on whether medical records document that informed, deliberate choices were made about formula selection or whether alternatives were discussed.
What Is the Current Status and What Might Families Expect Going Forward?
As of April 2026, the litigation remains in active trial and negotiation phases. Additional bellwether trials are scheduled throughout the year following the December 2025 plaintiff victory. These upcoming trials will continue to shape the landscape of the litigation—if juries continue to award substantial damages to plaintiffs, manufacturers may feel pressure to negotiate a broader settlement. Conversely, if some bellwether trials result in defense verdicts or lower damage awards, the negotiation dynamics might shift.
The eventual outcome could take several forms: continued individual trials for families who opt into the litigation, a limited settlement covering a subset of claims, or a comprehensive settlement addressing a larger group of affected families. Families should be aware that the path forward will likely depend on how many additional bellwether trials occur, what those verdicts show, and whether both sides reach a settlement agreement. Judge Pallmeyer’s management of the MDL will continue to set schedules and procedures. For families considering filing a claim or those already in the litigation, staying informed through their attorneys about trial schedules, settlement negotiations, and deadlines will be crucial. The financial recovery available to families—whether through verdict, settlement, or negotiated resolution—depends on providing strong evidence of formula use and NEC causation, maintaining documentation, and working with experienced attorneys who understand both the medical and legal aspects of these cases.
You Might Also Like
- Abbott Baby Formula Contamination Recall Class Action
- NEC Baby Formula Premature Infant Mass Tort Litigation
- Wilmington Community Clinic Data Breach Class Action Settlement
Open Settlements You Can Claim Now
Browse current class action settlements accepting claims — several require no proof of purchase: